The Norwegian company is entering into a clinical collaboration with the American biopharmaceutical company Nektar Therapeutics.
The aim of the collaboration is to explore positive effects from the combination of Vaccibody’s personalized cancer vaccine VB10.NEO and Nektar Therapeutics cancer drug NKTR-214. Pre clinical results of the combination are positive and the collaboration will mark the start of a clinical trial stage, reports the company.
The clinical trials will include patients with head and neck cancer and initially involve 10 patients.
Nasdaq Nektar Therapeutics market value is set as high as 10 billion dollars, reports Oslo Cancer Cluster.